| scholarly article | Q13442814 |
| P50 | author | Rafael Rosell | Q30003989 |
| Evangelos Pazarentzos | Q59545329 | ||
| Cristina Teixidó | Q59679580 | ||
| Samuel Brook | Q62829073 | ||
| Trever G Bivona | Q90929253 | ||
| P2093 | author name string | Yan Chen | |
| Angela Tam | |||
| José Baselga | |||
| Neal Rosen | |||
| Qing Sheng | |||
| Rita Das | |||
| Alan Huang | |||
| Ana Oaknin Benzaken | |||
| Darcy A Kerr | |||
| Dejan Juric | |||
| Huiqin Wang | |||
| Jenny Jiacheng Yan | |||
| Jinsheng Liang | |||
| Jordi Rodon | |||
| Joseph M Gurski | |||
| Manway Liu | |||
| Maurizio Scaltriti | |||
| Moshe Elkabets | |||
| Natasha Morse | |||
| Raphael A Pelossof | |||
| Ronald A Ghossein | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay | Q24312603 | ||
| Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C | Q24561989 | ||
| Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 | ||
| Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers | Q27852227 | ||
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials | Q27852946 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| A novel putative tyrosine kinase receptor with oncogenic potential | Q28273122 | ||
| Genomic and molecular characterization of esophageal squamous cell carcinoma | Q28657686 | ||
| The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor | Q28678514 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 | Q29614651 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma | Q31096247 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 | ||
| AXL mediates resistance to cetuximab therapy | Q34204829 | ||
| Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth | Q34371882 | ||
| Identification of genomic alterations in oesophageal squamous cell cancer | Q34412178 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| Protein kinase C, an elusive therapeutic target? | Q37141320 | ||
| EGFR signals to mTOR through PKC and independently of Akt in glioma | Q37476332 | ||
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer | Q37605004 | ||
| The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells | Q37627397 | ||
| PKC and the control of localized signal dynamics. | Q37679691 | ||
| The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. | Q38104686 | ||
| Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. | Q39097045 | ||
| Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Q39813764 | ||
| Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase | Q40266943 | ||
| Multiple roles for the receptor tyrosine kinase axl in tumor formation | Q40360957 | ||
| Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. | Q41527861 | ||
| R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer | Q43166849 | ||
| Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. | Q51825099 | ||
| The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. | Q54298179 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| esophageal squamous cell carcinoma | Q108442577 | ||
| P304 | page(s) | 533-46 | |
| P577 | publication date | 2015-04-13 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas | |
| P478 | volume | 27 |
| Q58776119 | A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma |
| Q37665524 | A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer |
| Q90148023 | AXL as a Target in Breast Cancer Therapy |
| Q60907785 | AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells |
| Q64073169 | AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells |
| Q50053695 | AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma |
| Q64104777 | AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer |
| Q38672995 | AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients |
| Q37702320 | Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas |
| Q37628915 | Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation |
| Q92821373 | Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations |
| Q89728271 | Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer |
| Q41953242 | Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. |
| Q38936702 | Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer? |
| Q42365122 | Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells |
| Q63884105 | Bosutinib Inhibits EGFR Activation in Head and Neck Cancer |
| Q40475630 | Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Q100464024 | CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor |
| Q37581008 | CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma |
| Q92339199 | Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors |
| Q37295326 | Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer. |
| Q92323801 | Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors |
| Q52716291 | Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells via mTOR activation through Akt-independent pathway. |
| Q58746752 | Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips |
| Q48243258 | Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. |
| Q50027355 | Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer |
| Q89860520 | Current Advances in the Treatment of BRAF-Mutant Melanoma |
| Q38888022 | Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer |
| Q64258088 | Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl |
| Q38539217 | Drugging PI3K in cancer: refining targets and therapeutic strategies |
| Q90703606 | EGFR inhibitor AG1478 blocks the formation of 3D structures mainly through ERK signaling pathway in Matrigel-induced 3D reconstruction of eccrine sweat gland-like structures |
| Q38964435 | Emerging role of mTOR in the response to cancer therapeutics |
| Q96762441 | Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers |
| Q49887971 | Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. |
| Q38387634 | Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma |
| Q47988269 | Four PTEN-targeting co-expressed miRNAs and ACTN4- targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue |
| Q49636410 | Function of Axl receptor tyrosine kinase in non-small cell lung cancer |
| Q90324835 | Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance |
| Q50862689 | Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages. |
| Q36970393 | Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling |
| Q38763966 | Gene of the month: Axl. |
| Q50917827 | Genomic insights into head and neck cancer. |
| Q38772267 | Giving AXL the axe: targeting AXL in human malignancy |
| Q93000077 | HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma |
| Q26749159 | Hypoxic control of metastasis |
| Q58712237 | IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer |
| Q89973252 | IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma |
| Q92027154 | Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization |
| Q101226383 | Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis |
| Q38702479 | Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. |
| Q37545045 | Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies |
| Q50113702 | Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer |
| Q39157476 | Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies |
| Q50116331 | Leveraging Genomics for Head and Neck Cancer Treatment |
| Q99721505 | Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer |
| Q58582644 | Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines |
| Q28070028 | Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy |
| Q38972265 | New twists in the AXL(e) of tumor progression |
| Q92593655 | Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma |
| Q37716027 | Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition |
| Q36274292 | PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors |
| Q101133481 | Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity |
| Q38892190 | Personalized and targeted therapy of esophageal squamous cell carcinoma: an update |
| Q99579024 | Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma |
| Q41889905 | Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia |
| Q38684394 | Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. |
| Q47202432 | Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma |
| Q41847773 | Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. |
| Q64891848 | Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression. |
| Q40578862 | Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. |
| Q92296438 | Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy |
| Q91320660 | SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth |
| Q52356988 | Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. |
| Q41940444 | Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity |
| Q36909843 | Squamous Cell Cancers: A Unified Perspective on Biology and Genetics |
| Q89393296 | Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer? |
| Q40591054 | Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer |
| Q89578339 | TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer |
| Q39441303 | Targeting PI3K Signaling in Combination Cancer Therapy. |
| Q63447350 | Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer |
| Q57453842 | Targeting glutamine metabolism in mutant colorectal cancers |
| Q57453835 | Targeting glutamine metabolism inPIK3CAmutant colorectal cancers |
| Q27853383 | The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma |
| Q57470611 | The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview |
| Q37017948 | The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR |
| Q51146366 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. |
| Q28068756 | The Receptor Tyrosine Kinase AXL in Cancer Progression |
| Q101564368 | The nuclear export protein XPO1 - from biology to targeted therapy |
| Q49238007 | The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review |
| Q39042140 | The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor |
| Q89121009 | The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer |
| Q93380660 | Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer |
| Q47141265 | Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. |
| Q37618946 | Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. |
| Q91673663 | Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer |
| Q38764654 | Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer |
| Q57472231 | Weak power frequency magnetic fields induce microtubule cytoskeleton reorganization depending on the epidermal growth factor receptor and the calcium related signaling |
| Q39456830 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. |
| Q64889726 | mTOR Signalling in Head and Neck Cancer: Heads Up. |
Search more.